https://www.bioworld.com/rss en-us Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732621 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732621-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system Shanghai Peptidstar Therapeutics Ltd. has divulged new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease. http://www.bioworld.com/articles/732557 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732557-shanghai-peptidstar-therapeutics-synthesizes-new-il-23r-antagonists Thioredoxin reductase 1 (TXNRD1) is a key component of the thioredoxin antioxidant system that helps maintain cellular redox homeostasis and regulates critical cellular processes such as proliferation, apoptosis and immune responses. A team of researchers at Central South University systematically investigated TXNRD1 expression and function in psoriatic keratinocytes using gene expression datasets, clinical samples and in vitro and in vivo models. http://www.bioworld.com/articles/732552 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732552-txnrd1-links-keratinocyte-hyperproliferation-and-inflammation-in-psoriasis-emerging-as-a-target Doctor holding illustration of cross section of skin While the emergence of immune checkpoint inhibitor (ICI) therapy in recent years has significantly improved cancer outcomes, some patients have been unable to experience the full therapeutic benefits of ICIs due to significant gastrointestinal inflammation linked to treatment. Seres Therapeutics Inc. is looking to change that with its live biotherapeutic candidate, SER-155, offering impressive findings from phase I data in ICI-related enterocolitis, or irEC. http://www.bioworld.com/articles/732435 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732435-seres-ser-155-takes-on-immune-checkpoint-inhibitor-related-enterocolitis Illustration of intestinal track Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732430 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732430-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732480 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732480-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system Beijing Double-Crane Runchuang Technology Co. Ltd. has discovered new Toll-like receptor 7 (TLR7) and/or TLR8 antagonists potentially useful for the treatment of rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis, hidradenitis suppurativa, polymyositis, psoriasis and Sjogren’s syndrome, among others. http://www.bioworld.com/articles/732410 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732410-beijing-double-crane-runchuang-identifies-new-tlr7-8-antagonists Merck Sharp & Dohme LLC (MSD) has synthesized new benzimidazole derivatives acting as NLRP3 inflammasome inhibitors. As such, they are potentially useful for the treatment of atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune disease, Alzheimer’s and Parkinson’s disease, among others. http://www.bioworld.com/articles/732386 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732386-nlrp3-inflammasome-inhibitors-disclosed-in-msd-patent Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s architecture is shaped through the organization of tissues, the establishment of molecular pathways, and the coordination of signals that will later sustain the body as an integrated system. It is likely the most delicate stage of life, where any disturbance in that foundational process can have lasting consequences on health. http://www.bioworld.com/articles/732374 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732374-cinp-2026-prenatal-and-adolescent-stress-shape-brain-vulnerability Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front. http://www.bioworld.com/articles/732348 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732348-nuvectis-shares-continue-to-rally-after-146b-haisco-deal Dollar symbol with arrow graph Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis. http://www.bioworld.com/articles/732324 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732324-hexapharmatec-identifies-new-tfeb-inducers Changchun Genescience Pharmaceuticals Co. Ltd. has synthesized new molecular glue degraders comprising E3 ubiquitin-protein ligase-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are described as potentially useful for the treatment of ulcerative colitis, Crohn’s disease, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis. http://www.bioworld.com/articles/732216 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732216-changchun-genescience-pharmaceuticals-discloses-new-vav1-degradation-inducers Chronic activation or upregulation of interleukin-1 receptor-associated kinase 4 (IRAK4) has been linked to several diseases, including systemic lupus erythematosus, rheumatoid arthritis, atopic dermatitis, Alzheimer’s disease and atherosclerosis. Researchers from the Ocean University of China aimed to address the limitations of traditional small-molecule inhibitors by designing novel proteolysis targeting chimeras (PROTACs) for IRAK4 degradation. http://www.bioworld.com/articles/732208 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732208-irak4-targeting-protac-degrader-suppresses-inflammatory-signaling-in-vitro 3D rendering of interleukin-1 receptor-associated kinase 4 IRAK4, a protein kinase involved in signaling innate immune responses from Toll-like receptors. The EMA is recommending withdrawing Amgen Inc.’s complement inhibitor Tavneos (avacopan) from the market in Europe, saying data provided at the time it assessed the MAA “were found to be incorrect and misleading and could no longer be relied upon for demonstrating Tavneos’ effectiveness.” http://www.bioworld.com/articles/732171 Fri, 26 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732171-ema-to-pull-amgens-tavneos-over-incorrect-and-misleading-data Tavneos Credit: Amgen Inc. Receptor-interacting protein kinase 1 (RIPK1) acts as a central signaling node regulating apoptosis, necroptosis and inflammatory pathways. Researchers from China Pharmaceutical University reported the discovery and preclinical characterization of LT-1339-553, a novel RIPK1 inhibitor, in models of schistosomiasis-induced hepatic fibrosis. http://www.bioworld.com/articles/732192 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732192-new-ripk1-inhibitor-protects-from-hepatic-fibrosis 3D molecular model illustration of RIPK1 RIPK1 Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front. http://www.bioworld.com/articles/732081 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732081-nuvectis-shares-continue-to-rally-after-146b-haisco-deal Dollar symbol with arrow graph Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. http://www.bioworld.com/articles/732184 Wed, 24 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732184-pulmonary-inflammation-unveils-three-severe-pneumonia-subtypes Lungs anatomy J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment. http://www.bioworld.com/articles/732153 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732153-j-pharma-drives-first-cancer-lat1-to-phase-iii-study-with-fda-nod Illustration of cancer in the bile ducts Researchers from Bayer AG reported the discovery and preclinical characterization of BAY-439, a potent and selective hPLA2-G5 inhibitor, in models of pain. http://www.bioworld.com/articles/732114 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732114-hpla2-g5-inhibition-exerts-analgesic-and-anti-inflammatory-effects Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. Some patients with severe pneumonia progress in different ways. Predicting their trajectories could help tailor treatments and prevent fatal outcomes. To do this, the scientists analyzed bronchoalveolar fluid from several patient cohorts and identified three biological pneumotypes based on which cells are present, which genes are active, and which inflammatory proteins are produced. http://www.bioworld.com/articles/732108 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732108-pulmonary-inflammation-unveils-three-severe-pneumonia-subtypes Lungs anatomy Asahi Kasei Therapeutics Corp. has identified new tumor necrosis factor receptor superfamily member 1A (TNFRSF1A; TNFR1; p55; CD120a) antagonists potentially useful for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, hidradenitis suppurativa, ulcerative colitis and Crohn's disease. http://www.bioworld.com/articles/732105 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732105-asahi-kasei-therapeutics-reports-new-tnfr1-antagonists Haisco Pharmaceutical Group Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN)-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis and gastroenteritis. http://www.bioworld.com/articles/732040 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732040-new-vav1-degradation-inducers-reported-in-haisco-pharmaceutical-group-patents J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment. http://www.bioworld.com/articles/731921 Thu, 18 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731921-j-pharma-drives-first-cancer-lat1-to-phase-iii-study-with-fda-nod Illustration of cancer in the bile ducts Shanghai Pharmaceuticals Holding Co. Ltd. has reported interleukin-17A (IL-17A) inhibitors that are potentially useful for the treatment of psoriasis, rheumatoid arthritis, spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis and uveitis. http://www.bioworld.com/articles/732020 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732020-shanghai-pharmaceuticals-discovers-new-il-17a-inhibitors Spyre Therapeutics Inc.’s striking “two for two” data on ulcerative colitis (UC) candidates, SPY-001 and SPY-002, drew applause from multiple analysts, putting eyes on the Boston biotech’s upcoming top-line data of anti-IL-23 antibody SPY-003 – the third biologic module in a six-strong inflammatory bowel disease (IBD) lineup. http://www.bioworld.com/articles/731905 Wed, 17 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731905-spyres-skyline-uc-double-win-lifts-hopes-for-ibd-antibody-combos Gastrointestinal system Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant colony-stimulating factor 1 receptor inhibitor, with plans to move the asset into a biomarker-based and placebo-controlled study. http://www.bioworld.com/articles/731984 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731984-elixirons-enrupatinib-shows-upbeat-interim-phase-ii-ad-results Illustration of amyloid plaques in Alzheimer's disease Wuhan Createrna Science and Technology Co. Ltd. has synthesized new cyclobutenedione compounds acting as C-C chemokine receptor type 6 (CCR6) antagonists potentially useful for the treatment of inflammatory bowel disease, allergy, dry eye, psoriasis, rheumatoid arthritis and multiple sclerosis. http://www.bioworld.com/articles/731970 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731970-ccr6-antagonists-disclosed-in-wuhan-createrna-patent Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant colony-stimulating factor 1 receptor inhibitor, with plans to move the asset into a biomarker-based and placebo-controlled study. http://www.bioworld.com/articles/731877 Mon, 15 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731877-elixirons-enrupatinib-shows-upbeat-interim-phase-ii-ad-results Illustration of amyloid plaques in Alzheimer's disease More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways involving complement factor 5 and its receptor (C5aR1) were overexpressed, and that a C5aR1 antagonist, avacopan, reduced the need for glucocorticoids and improved renal recovery. This led researchers to investigate the association of anti-C5aR1 antibodies with GCA and its outcomes. http://www.bioworld.com/articles/731857 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731857-anti-c5ar1-antibodies-linked-to-outcomes-in-giant-cell-arteritis Medical illustration showing layers of a blood vessel CD45RC is an isoform of protein tyrosine phosphatase receptor type C, a protein that plays a key role in regulating antigen receptor signaling in T and B cells. While it is expressed on most circulating B cells, it is only highly expressed on Th1 precursors, Th1 cells and T effector memory CD45RA+ cells (TEMRA). http://www.bioworld.com/articles/731838 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731838-cd45rc-identified-as-therapeutic-target-in-sjogren-disease